文献速递白血病

PTP4A2通过抑制p53通路促进白血病起始细胞白血病发生

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.
PubMed 文献 · Blood Adv · 2026-01-01

该研究以KMT2A-MLLT3驱动的急性髓系白血病(AML)为模型,发现PTP4A2缺失可激活p53、诱导白血病起始细胞(LIC)凋亡和衰老,从而延长受体小鼠生存;机制上PTP4A2直接结合p53并使其Ser392去磷酸化,降低p53稳定性和活性,促进LIC增殖与存活。

要点

  • PTP4A2在AML中高表达,通过抑制p53通路维持LIC。
  • PTP4A2缺失激活p53,诱导LIC凋亡和衰老。
  • PTP4A2直接使p53 Ser392去磷酸化,降低其稳定性。

核心结论

  • PTP4A2通过抑制p53肿瘤抑制通路促进白血病起始细胞的维持和白血病发生。
  • p53是白血病细胞中PTP4A2的潜在底物。

研究设计与样本

  • 使用KMT2A-MLLT3驱动的AML模型,比较Ptp4a2-/-与对照LICs在受体小鼠中的 repopulation 能力。

主要发现

  • PTP4A2缺失激活p53,诱导LIC凋亡和衰老,延长受体小鼠生存。
  • PTP4A2直接与p53相互作用,使其Ser392去磷酸化,降低p53稳定性和活性。
  • PTP4A2增强LIC增殖和存活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3-driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2-/- LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Xiao S, Kobayashi M, Bai Y, et al. PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells. Blood Adv. 2026. PMID: 41985006. doi:10.1182/bloodadvances.2025018908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。